ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+9.79%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$786M
AUM Growth
+$786M
(+10%)
Cap. Flow
+$7.7M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
59.84%
Holding
34
New
8
Increased
8
Reduced
7
Closed
6
Top Buys
| 1 |
Labcorp
LH
|
$43.4M |
| 2 |
Align Technology
ALGN
|
$37.9M |
| 3 |
AbbVie
ABBV
|
$32.5M |
| 4 |
Pulmonx
LUNG
|
$27.4M |
| 5 |
Encompass Health
EHC
|
$22.5M |
Top Sells
| 1 |
Exact Sciences
EXAS
|
$52.7M |
| 2 |
HCA Healthcare
HCA
|
$46M |
| 3 |
DexCom
DXCM
|
$27.7M |
| 4 |
Vericel Corp
VCEL
|
$23.3M |
| 5 |
Heron Therapeutics
HRTX
|
$18.3M |
Sector Composition
| 1 | Healthcare | 98.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Encompass Health
EHC
$12.3B
| $63.5M | 8.07% | 775,000 +275,000 | +55% | +$22.5M |
|
2
UnitedHealth
UNH
$281B
| $59.5M | 7.57% | 160,000 +27,558 | +21% | +$10.3M |
|
3
Zimmer Biomet
ZBH
$21B
| $59.2M | 7.53% | 370,000 | – | – |
|
4
Molina Healthcare
MOH
$9.8B
| $46.8M | 5.94% | 200,000 +50,000 | +33% | +$11.7M |
|
|
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $46M | 5.85% | 500,000 -150,000 | -23% | -$13.8M |
|
|
6
Labcorp
LH
$23.1B
| $43.4M | 5.51% | +170,000 | New | +$43.4M |
|
7
Charles River Laboratories
CRL
$8.04B
| $40.6M | 5.16% | 140,000 | – | – |
|
|
8
Align Technology
ALGN
$10.3B
| $37.9M | 4.82% | +70,000 | New | +$37.9M |
|
9
Envista
NVST
$3.52B
| $37.1M | 4.72% | 910,000 +9,313 | +1% | +$380K |
|
10
Haemonetics
HAE
$2.63B
| $36.6M | 4.66% | 330,000 +54,547 | +20% | +$6.06M |
|
|
11
AbbVie
ABBV
$372B
| $32.5M | 4.13% | +300,000 | New | +$32.5M |
|
12
Surgery Partners
SGRY
$2.91B
| $32.1M | 4.08% | 725,000 -194,338 | -21% | -$8.6M |
|
13
Pacific Biosciences
PACB
$393M
| $31.2M | 3.96% | 935,805 +135,805 | +17% | +$4.52M |
|
|
14
Pulmonx
LUNG
$69.7M
| $27.4M | 3.49% | +600,000 | New | +$27.4M |
|
15
CONMED
CNMD
$1.68B
| $26.1M | 3.32% | 200,000 +51,683 | +35% | +$6.75M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $25.1M | 3.19% | 180,000 +11,239 | +7% | +$1.57M |
|
17
IQVIA
IQV
$32.4B
| $19.3M | 2.46% | 100,000 -43,020 | -30% | -$8.31M |
|
|
OSH
18
DELISTED
Oak Street Health, Inc.
OSH
| $19M | 2.42% | +350,000 | New | +$19M |
|
19
Idexx Laboratories
IDXX
$51.8B
| $17.1M | 2.18% | +35,000 | New | +$17.1M |
|
20
Guardant Health
GH
$8.41B
| $15.3M | 1.94% | 100,000 -66,000 | -40% | -$10.1M |
|
21
Natera
NTRA
$23.1B
| $15.2M | 1.94% | 150,000 | – | – |
|
|
22
Exact Sciences
EXAS
$8.98B
| $13.2M | 1.68% | 100,000 -400,000 | -80% | -$52.7M |
|
|
DMTK
23
DELISTED
DermTech, Inc. Common Stock
DMTK
| $12.7M | 1.61% | +250,000 | New | +$12.7M |
|
|
OHPAU
24
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $11M | 1.4% | +1,100,000 | New | +$11M |
|
|
25
Vericel Corp
VCEL
$1.83B
| $8.89M | 1.13% | 160,000 -420,000 | -72% | -$23.3M |
|